SCHEMBL2854739

SCHEMBL2854739

S=[C]Nc1n[nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.50
KDM4E B2RXH2 4/20 0.48
GAA P10253 2/20 0.48
ALDH1A1 P00352 2/20 0.48
IDO1 P14902 2/20 0.48
MAPK10 P53779 2/20 0.48
ALPL P05186 1/20 0.48
HPGD P15428 1/20 0.48
TTK P33981 1/20 0.48
PDPK1 O15530 1/20 0.47
CYP3A4 P08684 1/20 0.47
FADS1 O60427 2/20 0.46
ADRA2A P08913 2/20 0.46
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
GRM4 Q14833 1/20 0.41
AURKA O14965 1/20 0.41
CYP1A2 P05177 1/20 0.41
YTHDC1 Q96MU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966349 0.81 TRPA1 (0.50) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL31032755 0.75 TRPA1 (0.54) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL7452500 0.75 TRPA1 (0.54) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL15392392 0.75 TRPA1 (0.54) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL11756891 0.75 TRPA1 (0.54) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL7172053 0.75 TRPA1 (0.54) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL11700794 0.75 KDM4E (0.57) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL3071686 0.73 TRPA1 (0.49) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL29882003 0.72 TRPA1 (0.75) TRPA1KDM4EGAAALDH1A1IDO1
SCHEMBL4741513 0.72 TRPA1 (0.75) TRPA1KDM4EGAAALDH1A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786079-B2 Substituted nonadepsipeptides AICURIS GMBH & CO. KG. (DE) 2010-08-31 US disclosed
EP-1809653-B1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2010-01-20 EP disclosed
US-20080058251-A1 Substituted nonadepsipeptides BAYER HEALTHCARE AG (DE) 2008-03-06 US disclosed
EP-1809653-A1 SUBSTITUTED NONADEPSIPEPTIDES AiCuris GmbH & Co. KG (DE) 2007-07-25 EP disclosed
WO-2006042654-A1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO. KG (DE) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058251-A1 Substituted nonadepsipeptides VIP, DNPEP, LNPEP TRPA1 3125/4885KDM4E 4730/4885GAA 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.